‹ News

KLIC AIRG Q UI CRS ARCT ANL KEYS MLTX RVLV

ARCT: Rounding Bottom detected on 9 Apr 2026

All prices, scores, and news on this page reflect data available before market open on 9 Apr 2026.

Overall Score

78 of 100

Good

Win Probability

64%

Moderate

Reward / Risk

0.2 : 1

$0.06 reward $-0.24 risk

Summary Context Technical Indicators

Current Setup

Arcturus Therapeutics is executing a strategic shift back to rare disease applications, and the rounding bottom pattern forming reflects this repositioning. The pattern shows structure quality of 13.75/15 and breakout strength of 13.0/13, with volume confirmation at 12.0/12. Price sits at $8.50, between support at $5.85 and resistance at $14.53, 45% above the 52-week low but 65% below the 52-week high. Volume ratio of 1.12x average signals mild accumulation as the rounded bottom base completes. The 77.75 overall score and 64.22% win probability suggest modest technical merit for a push toward $9.07 conservative target.

Stock Context

ARCT-810 for OTC deficiency is advancing with FDA engagement planned for Q2 2026 feedback, while ARCT-032 for cystic fibrosis has a 12-week study planned to assess lung function improvement using a 10 mg dose. Interim Phase 2 CF data showed mucus plug reduction in four of six Class I CF participants using AI-enhanced imaging analysis. Cash runway extends into Q2 2028, excluding milestone payments. However, sentiment remains divided: FDA has delayed KOSTAIVE BLA and demands new COVID-19 efficacy data, and HC Wainwright has materially lowered FY2026 EPS forecasts and extended losses into 2029-2030. The rounding bottom is forming as biotech investors digest both clinical progress and regulatory setbacks simultaneously.

What to Expect

A successful rounding bottom breakout would target $9.07 (conservative measure), requiring follow-through above key resistance at $14.53 to extend gains. Volume should remain above 565k average on any surge—current 635k shows marginal strength. The invalidation level sits at $5.85 support; a close below that price would negate the bullish pattern structure. With 64.22% historical win probability for this pattern type, the setup indicates roughly 2:1 odds favoring upside, though modest breakout score of 13.0 suggests a contained initial move rather than violent acceleration. RSI at 67.4 approaches overbought territory but hasn't triggered extreme reading yet.

Risk Factors

FDA delays on KOSTAIVE BLA and new COVID-19 efficacy data demands create near-term headwind. HC Wainwright cut FY2026 EPS from ($2.19) to ($3.07) and projects substantial losses extending through 2030, signaling analyst capitulation. Citigroup slashed price target from $66 to $21 though maintained buy—reducing conviction. High beta of 1.34 and 20-day volatility of 66.89% amplify drawdown risk in sector weakness. ARCT-810 pivotal development hinges on Type C FDA regulatory meetings H1 2026—adverse guidance could derail the rounding bottom thesis. Additional funding needed to complete Phase III trials for both programs creates dilution risk if cash cannot be stretched through data readouts.

Market & Sector Regime

Market

Bullish 0.87

-1.0 0 +1.0

Health Care Sector

Bullish 0.62

-1.0 0 +1.0

Overall Score

39 of 40

Exceptional

Pattern Quality

20 of 20

Exceptional

Setup

11 of 20

Fair

R/R

8 of 18

Weak

Context

Pattern Quality Score

14 of 15

Exceptional

Structure

13 of 13

Exceptional

Breakout

12 of 12

Exceptional

Volume

Recent Performance

+10.1%

+27.8%

+15.5%

+28.6%

Momentum & Trend

RSI (14)

67.4

Neutral

MACD Histogram

+0.18

Bullish

Bollinger Band Position

97.1%

Upper Band

Volatility & Risk

20-Day Volatility

0.67

Very High

ATR %

6.1%

High

Beta

1.34

Above Mkt

Volume Analysis

Volume Ratio

1.12x

Average

20-Day Avg Vol

567K

shares / day

Current Volume

636K

shares traded

Price Levels

52W High

$24.17

Resistance

$14.53

Target

$9.07

Current

$8.50

Stop Loss

$7.73

Support

$5.85

52W Low

$5.85

Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.